Diabetes and glycaemic-control evidence summaries covering HbA1c, glucose monitoring, medication comparisons, hypoglycaemia, patient-reported outcomes, and clinical interpretation.
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.
A 78-patient randomised placebo-controlled trial of the GLP-1 analogue Ebenatide in type 2 diabetes, with a between-group glycaemic edge at Week 24 only. PICO summary and expert commentary.
COMBINE 2 found once-weekly IcoSema superior to semaglutide 1.0 mg for HbA1c in type 2 diabetes, but body weight significantly favoured semaglutide. PICO summary and expert commentary.
A small single-centre RCT of CGM-guided individualised care versus self-monitoring in 80 women with diabetes in pregnancy, with no between-group glycaemic superiority demonstrated. PICO summary and expert commentary.
Acute empagliflozin produced robust, comparable urinary glucose excretion in HNF1A-MODY and type 2 diabetes during a hyperglycaemic clamp. PICO summary and expert commentary.
A 1-year randomised controlled trial of pharmacist-led collaborative care versus standard care in 400 adults with type 2 diabetes, reporting EQ-5D and visual analogue scale quality-of-life gains alongside a larger HbA1c reduction. PICO summary and expert commentary.
A small single-blind RCT testing whether a family-centered empowerment program improves patient-reported illness acceptance and self-management in type 2 diabetes. PICO summary and expert commentary.
In QWINT-3, once-weekly insulin efsitora alfa was non-inferior to once-daily degludec for HbA1c lowering in basal-insulin-treated type 2 diabetes, with comparable hypoglycaemia. PICO summary and expert commentary.
QWINT-4 phase 3 trial: once-weekly insulin efsitora alfa was non-inferior to daily glargine U100 for HbA1c in basal-prandial-treated type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of the DIVERSITY-CVR trial tests whether baseline ALT predicts differential HbA1c and time-in-range responses to dapagliflozin versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
